Timing of local treatment for limited metastatic stomach or esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving local treatments (like surgery or radiation) to cancer spots later—after starting immunotherapy or targeted therapy—helps people with stomach or esophageal cancer that has spread to a few places. It aims to improve outcomes by timing treatments carefully.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a limited number of cancer spots (metastases) that can be treated with surgery or radiation.
- Your tumor has a marker like PD-L1, HER2, or Claudin 18.2 that allows you to receive immunotherapy or targeted therapy.
- You have not had any prior chemotherapy or other systemic treatment for cancer that has spread.
- You are healthy enough to undergo both local treatments and systemic therapy for at least 18 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan that combines chemotherapy with immunotherapy, followed by surgery, for people whose esophageal or stomach cancer has spread to a few areas (oligometastatic). The goal is to see if this approach can shrink the cancer and improve outcomes.
This trial tests a combination of chemotherapy drugs (nab-paclitaxel, oxaliplatin, and S-1) plus an immunotherapy drug (sintilimab) given before surgery for younger people (ages 16 to 45) with stomach or gastroesophageal junction cancer that can be removed. The goal is to see if this approach shrinks tumors and improves outcomes.
This trial tests whether adding targeted radiation or other local treatments can help people with esophageal cancer that has spread to only a few spots (up to 4) after they've been treated with a PD-1 inhibitor. It aims to control the cancer better and improve outcomes.
This trial tests a combination of an immunotherapy drug (PD-1 antibody) plus chemotherapy or targeted therapy, followed by surgery, for people with stomach cancer that has spread to a limited number of other sites. The goal is to see if this approach can help shrink the cancer enough to make surgery more effective.
This trial tests combining chemotherapy, immunotherapy, and radiation before surgery for stomach or gastroesophageal junction cancer that has spread to a limited number of sites. The goal is to see if this approach can improve outcomes by shrinking tumors before they are removed.
This trial tests giving immunotherapy (PD-1 inhibitors) along with local treatments like radiation or surgery at different times for patients whose esophageal cancer has spread to only a few spots. The goal is to see the best timing for these combined treatments.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.